MARKET EYE-Credit Suisse upgrades Dr Reddy's on US outlook

Thu Dec 13, 2012 9:15am IST

Related Topics

Stocks

   

* Credit Suisse upgrades Dr. Reddy's Laboratories to
'outperform' from 'neutral' and raises its target price to 2,150
rupees from 1,900 rupees, citing expectations for a strong pick
up in U.S. sales in the coming quarters.
* Credit Suisse also notes the market share for Dr. Reddy's
Metoprolol drug, used for hypertension, is increasing.
* Dr. Reddy's also expects upcoming approval of two limited
competition products in the United States, Credit Suisse says
after meeting with the drug maker's management.
* Dr. Reddy's also expects fiscal 2015 growth in the United
States to be stronger than fiscal 2014 due to some "significant"
launches.

 (abhishek.vishnoi@thomsonreuters.com /;
abhishek.vishnoi.reuters.com@reuters.net)
FILED UNDER:

Reuters Showcase

Land Ordinance

Land Ordinance

Modi says willing to make changes in land decree  Full Article 

Sahara Woes

Sahara Woes

SEBI cancels Sahara's portfolio management licence  Full Article 

Gold Demand

Gold Demand

India gold demand muted, eyes cut in import duty  Full Article 

Coffee's Hot

Coffee's Hot

IPO could value Cafe Coffee Day at $1 billion  Full Article 

Sahara Salaries

Sahara Salaries

Some staff say Sahara has not paid salaries for months   Full Article 

DLF Fined

DLF Fined

DLF says reviewing $8.4 million SEBI penalty  Full Article 

GM Corn

GM Corn

Monsanto says GM corn trial in final stage in India  Full Article 

Rail Budget

Rail Budget

Breakingviews - India goes back to future with $137 bln rail push  Full Article | Full Coverage 

Clean Energy

Clean Energy

India says clean energy a $160 billion opportunity over five years  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device  Full Coverage